References
- Asahara K, Ando Y, Tanaka Y, Yi S, Yamashita T, Ando M. Secondary hypoplastic anemia in patients with familial amyloidotic polyneuropathy. Acta Haematol 1993; 90: 130–135
- Beirao I, Lobato L, Costa P M, Fonseca I, Mendes P, Silva M, Bravo F, Cabrita A, Porto G. Kidney and anemia in familial amyloidosis type I. Kidney Int 2004; 66: 2004–2009
- Lobato L, Beirão I, Santos M, Azevedo R, Ribeiro P, Guimarães S. Intravenous iron and recombinant erythropoietin in the treatment of anemia in familial amyloid polyneuropathy. Amyloid and amyloidosis, R A Kyle, M Gertz. Parthenon Publishing Group, CarnforthUK 1999; 273–275
- Ando Y, Asahara K, Obayashi K, Suhr O, Yonemitsu M, Yamashita T, Tashima K, Uchino M, Ando M. Autonomic dysfunction and anemia in neurologic disorders. J Auton Nerv Syst 1996; 61: 145–148
- Spivak J L. Biologia de la eritropoyetina. Eritropoyetina humana recombinante, Chap 2, F Valderrábano. Masson SA, Barcelona 1998; 39–66
- Means R T, Jr, Krantz S B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639–1647
- Johnson R A, Cook C A, Furmanskl P. In vivo suppression of erythropoiesis by tumour necrosis factor alpha (TNF-α): reversal with exogenous erythropoietin. Exp Haematol 1990; 18: 109–115
- Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995; 5: 211–213
- Kawakami K, Abe H, Harayama N, Nakashima Y. Successful treatment of severe orthostatic hypotension with erythropoietin. Pacing Clin Electrophysiol 2003; 26: 105–107
- Pascual J, Teruel J L, Marcén R, Liaño F, Ortuño J. Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 1992; 15: 393–396
- Schaefer R M, Leschke M, Strauer B E, Heidland A. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol 1988; 8: 449–453
- Delamaire M, Durand F, Hamel D, Joyeux V, Lepogamp P, Genetet B. Improvement of hemorheologic parameters in hemodialyzed patients treated with human recombinant erythropoietin. J Mal Vasc 1991; 16: 289–294
- Bode-Böger S M, Böger R H, Kuhn M, Radermacher J, Frölich J C. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996; 50: 1255–1261
- Azzadin A, Mysliwiec J, Wollny T, Mysliwiec M, Buczko W. Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats. Thromb Res 1995; 77: 217–224
- Moreau C, Larivière R, Kingma I, Grose J H, Lebel M. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats. Clin Exp Hypertens 2000; 22: 663–674
- d'Uscio L V, Smith L A, Santhanam A V, Richardson D, Nath K A, Katusic Z S. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007; 49: 1142–1148
- Caravaca F, Pizarro J L, Arrobas M, Cubero J J, García M C, Perez-Miranda M. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994; 45: 845–851
- Lobato L, Beirão I, Silva M, Fonseca I, Queirós J, Rocha G, Sarmento A M, Sousa A, Sequeiros J. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid 2004; 11: 27–37
- Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006; 21: 330–336
- Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29: 327–335